Casirivimab Imdevimab (Regn-COV2) injection contains the active constituents Casirivimab and Imdevimab, which are monoclonal antibodies.
These antibodies attach to a protein on the surface of the coronavirus called the 'spike protein', preventing the virus from entering cells and causing infection.
They block the receptor binding domain (RBD) to the ACE2 receptor and prevent viral attachment to host cells.
Important information:
Do not take Casirivimab Imdevimab (Regn-COV2) injection if you are allergic to Casirivimab + Imdevimab or any other ingredients.
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional supplements, and herbal products.
Store in a refrigerator (2°C to 8°C), do not freeze.
Protect the medicine from light and excessive moisture.
Keep the medicine out of reach of children and pets.
If you missed the dosing schedule, inform your healthcare professional immediately and reschedule.
Administration:
Casirivimab Imdevimab (Regn-COV2) injection is given as an infusion into your vein that lasts for 20 to 30 minutes, or it can be given as a subcutaneous (under the skin) injection.
This injection will be given to you by a doctor or nurse who is experienced in the use of this type of treatment.
Do not self-administer this medicine.
Safety advice:
Pregnancy: there is limited information on the safety of Casirivimab Imdevimab (Regn-COV2) injection during pregnancy. Inform your physician if you are pregnant, suspecting, or planning for pregnancy.
Breastfeeding: there is limited information on the safety of Casirivimab Imdevimab (Regn-COV2) injection during breastfeeding. Inform your physician if you are breastfeeding.
Lungs: it is unknown whether Casirivimab Imdevimab (Regn-COV2) injection can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
Liver: there is limited information available on the use of Casirivimab Imdevimab (Regn-COV2) injection in patients with liver diseases. Inform your physician if you have any liver problems before initiating the treatment.
Alcohol: it is unknown whether it is safe to consume alcohol with Casirivimab Imdevimab (Regn-COV2) injection. Inform your physician if you are a chronic drinker.
Driving: Casirivimab Imdevimab (Regn-COV2) injection does not affect your ability to drive and operate heavy machinery. Inform your physician if you face any symptoms that alter your concentration.
Side effects:
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Serious side effects include hypersensitivity reaction and infusion reaction.
Common side effects may include infusion-related reactions such as swelling in the hands, face, and feet, skin rash, breathing difficulties, cough, abdominal pain, and chest pain.
Injection site reactions like swelling and redness at the injection site can also occur.
FAQs:
How effective is Casirivimab Imdevimab (Regn-COV2) injection in treating COVID-19?
Clinical studies have shown that Casirivimab Imdevimab (Regn-COV2) injection can significantly reduce the risk of hospitalization or death in high-risk individuals with COVID-19. However, the effectiveness may vary depending on individual factors, including the illness's severity and specific variants of the virus.
Can Casirivimab Imdevimab (Regn-COV2) injection be used in combination with other COVID-19 treatments?
Casirivimab Imdevimab (Regn-COV2) injection can be used alone or in combination with other COVID-19 treatments as determined by healthcare professionals. It is important to consult with healthcare providers to ensure proper coordination of treatments and minimize any potential interactions.
How soon after testing positive for COVID-19 should Casirivimab Imdevimab (Regn-COV2) injection be administered?
Casirivimab Imdevimab (Regn-COV2) injection is most effective when administered early after testing positive for COVID-19, ideally within 10 days of symptom onset. Early treatment helps reduce the severity of illness and the risk of hospitalization.
Can Casirivimab Imdevimab (Regn-COV2) injection be used in pediatric patients?
Yes, Casirivimab Imdevimab (Regn-COV2) injection is authorized for use in pediatric patients aged 12 years and older who weigh at least 35.5 kg and are at high risk of developing severe COVID-19.
Can Casirivimab Imdevimab (Regn-COV2) injection be used as a substitute for COVID-19 vaccination?
No, Casirivimab Imdevimab (Regn-COV2) injection is not a substitute for COVID-19 vaccination. Vaccination is the most effective way to prevent COVID-19 and its complications. This injection is specifically used to treat individuals who have already tested positive for the virus and are at high risk of developing the infection.
